Loading organizations...
§ Private Profile · Peabody, MA, USA
Biopharmaceutical company developing and commercializing biologic medicines for oncology and immunology, from biosimilars to novel therapies.
Innovent Biologics, based in Suzhou, China, develops, manufactures, and commercializes high-quality biologic medicines, primarily monoclonal antibodies, addressing unmet medical needs in oncology, immunology, and other therapeutic areas. The company has expanded its portfolio to over 10 approved products by early 2025 and frequently maintains a market capitalization exceeding 60 billion HKD. Innovent secured a $260 million Series D funding round in 2016, a record for China's biopharma sector at the time, attracting early investment from Fidelity Biosciences and Lilly Asia Ventures. Its diversified pipeline includes biosimilars and novel therapies, with key products like Tyvyt (sintilimab) and strategic collaborations, notably with Eli Lilly for ex-China commercialization rights. Innovent Biologics was established in August 2011 by Dr. Michael Yu. Its business model centers on publicly traded biopharmaceutical company generating revenue through product sales , collaborations, and licensing deals, initially funded by venture capital.
Innovent has raised $150.0M across 1 funding round.
Innovent has raised $150.0M in total across 1 funding round.
Innovent has raised $150.0M across 1 funding round. Most recently, it raised $150.0M Series E in April 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 29, 2018 | $150M Series E | Nick Chen | Ally Bridge Group, Cormorant Asset Management, Hillhouse Capital Group, Legend Capital, Lilly Asia Ventures, Rock Springs Capital, Taikang | Announced |
Innovent has raised $150.0M in total across 1 funding round.
Innovent's investors include Nick Chen, Ally Bridge Group, Cormorant Asset Management, Hillhouse Capital Group, Legend Capital, Lilly Asia Ventures, Rock Springs Capital, Taikang.